Filing Flows › Metagenomi Therapeutics (MGX) › Q1 2026 › vs Q1 2025
Metagenomi Therapeutics (MGX) Q1 2026 vs Q1 2025 (year over year)
Metagenomi Therapeutics's revenue fell $2.9M (-70%) from $4.1M in Q1 2025 to $1.2M in Q1 2026.
Metagenomi Therapeutics, Q1 2026: revenue $1.2M (-70% year over year), net loss $23.1M, operating cash flow −$21.2M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $1.2M | $4.1M | −$2.9M | -70% |
| Other income, net | $1.5M | $2.9M | −$1.3M | -47% |
| Net loss | $23.1M | $25.0M | −$2.0M | -8% |
| Costs & expenses | $25.8M | $32.0M | −$6.2M | -19% |
| Operating costs | $25.8M | $31.9M | −$6.1M | -19% |
| Income tax | $10K | $98K | −$88K | -90% |
| Research & development | $19.3M | $25.1M | −$5.8M | -23% |
| General & admin | $6.5M | $6.8M | −$270K | -4% |
| Operating cash sources | $25.0M | $27.1M | −$2.1M | -8% |
| Depreciation | $1.3M | $1.4M | −$83K | -6% |
| Share-based compensation | $2.6M | $2.9M | −$376K | -13% |
| Cash used in operations | $21.2M | $22.8M | −$1.7M | -7% |
| Net loss absorbed | $23.1M | $25.0M | −$2.0M | -8% |
| Working capital & other | $1.9M | $2.1M | −$146K | -7% |
Questions
How much did Metagenomi Therapeutics's revenue grow year over year in Q1 2026?
Metagenomi Therapeutics's revenue fell $2.9M (-70%) from $4.1M in Q1 2025 to $1.2M in Q1 2026.